The global age-related macular degeneration market was valued at $5,335.7 million in 2015, and it is expected to grow at a CAGR of 7.6% during 2016 – 2022.
Among the various types, the wet AMD segment is expected to witness the faster growth compared to dry AMD segment, during the forecast period. The global age-related macular degeneration market is growing at a significant rate, due to increasing healthcare cost, and increasing prevalence lifestyle associated diseases, such as obesity and hypertension. In addition, the growing geriatric population, increasing prevalence of AMD and increasing pipeline drugs for AMD are also driving the growth of the global age-related macular degeneration market.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market/report-sample
Geographically, North America dominated the global market of age-related macular degeneration in 2015; whereas, the Asia-Pacific market is expected to witness the fastest growth, during the forecast period.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=age-related-macular-degeneration-market
Some of the key companies operating in the global age-related macular degeneration market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences, Inc.Source: Click here